Search Results

You are looking at 81 - 90 of 1,744 items for :

  • "chemotherapy" x
Clear All
Full access

Gary H. Lyman

Dr. Lyman has disclosed that he receives research grant support from Amgen Inc. References 1 Crawford J Dale DC Kuderer NM . Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of

Full access

Matthieu Picard, Ursula A. Matulonis and Mariana Castells

Ovarian cancer is the leading cause of death among gynecologic malignancies and ranks fifth in overall cancer-related mortality among women in the United States. 1 Chemotherapy, particularly with a taxane and platinum combination, is key to

Full access

Robert McNulty

in oncology: update 2006 . J Clin Oncol 2006 ; 24 : 2932 – 2946 . 3. Cancer Care Ontario: use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy , 2003 . Available at: http

Full access

Pankaj Singhal and Shashikant Lele

58 . 14. Kirmani S Braly PS McClay EF . A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer . Gynecol Oncol 1994 ; 54 : 338 – 344 . 15. Alberts DS Liu PY Hannigan EV

Full access

Daniel Morgensztern and Ramaswamy Govindan

. 7. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group . BMJ 1995 ; 311 : 899 – 909 . 8. Scagliotti

Full access

Holly Dushkin and Massimo Cristofanilli

Inflammatory breast tumors are more likely to have mutations in p53 , associated with decreased response to chemotherapy and decreased survival outcomes. 13 Several genes have been identified that are believed to contribute to the aggressive nature of IBC

Full access

Robert F. Ozols

cancer . Cancer Treat Rep 1978 ; 62 : 1 – 11 . 8 Markman M . Intraperitoneal chemotherapy . Semin Oncol 1991 ; 18 : 248 – 254 . 9 Markman M Reichman B Hakes T . Evidence supporting the superiority of intraperitoneal cisplatin

Full access

Michaela A. Dinan, Bradford R. Hirsch and Gary H. Lyman

emetogenic chemotherapy, multidrug chemotherapy regimens in patients for whom single agents will suffice, routine surveillance PET scans, prostate-specific antigen screening in patients with an expected lifespan of less than 10 years, and the use of targeted

Full access

Barbara Todaro

The management of chemotherapy-induced nausea and vomiting (CINV) has improved over the past 20 years. Before the introduction of 5-hydroxytryptamine (5-HT3) receptor antagonists, treatment options were limited to less-effective and more

Full access

Prajnan Das, Norio Fukami and Jaffer A. Ajani

– 11 . 30. Earle CC Maroun JA . Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials . Eur J Cancer 1999 ; 35 : 1059 – 1064 . 31. Janunger KG